Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2878 • 2019 ACR/ARP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip Mease¹, Saima Chohan ², Ferran J. García Fructuoso ³, Alice Gottlieb ⁴, Richard C. Chou ⁵, Alan Mendelsohn ⁶, Rocco Ballerini ⁶ and Michael E. Luggen ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, AZ, USA, Phoenix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁶Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁷Cincinnati Rheumatic Disease Study Group, Inc. and University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the…
Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Joseph Tkacz ¹, Ervant Maksabedian², Philip Chan ¹, Brendan Limone ¹, Alexis Ogdie ³, Elaine Karis ⁴ and Bradley Stolshek ², ¹IBM Watson, Bethesda, MD, ²Amgen Inc., Thousand Oaks, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc, Thousand Oaks, CA
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
Abstract Number: 1004 • 2019 ACR/ARP Annual Meeting
Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis
Cuong Nguyen¹, Trevor Chan ², Ilias Tagkopoulos ², Matthias Eberl ³ and Iannis Adamopoulos ¹, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, Sacramento, CA, ²University of California, Davis, Department of Computer Science, California, USA, Davis, CA, ³Division of Infection and Immunity, School of Medicine and Systems Immunity Research Institute, Cardiff University, Cardiff CF14 4XN, United Kingdom, Cardiff, United Kingdom
Background/Purpose: γδ T cells are non-conventional lymphocytes that straddle between innate and adaptive immunity. Although γδ T cells have been implicated in psoriatic arthritis, the…
Abstract Number: 1203 • 2019 ACR/ARP Annual Meeting
Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review
M. Elaine Husni¹, Mark Kosinski ², Regina Rendas-Baum ², Shelly Kafka ³, Chenglong Han ⁴, Eric K H Chan ⁴, Elizabeth Hsia ⁵ and Arthur Kavanaugh ⁶, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Optum, Johnston, RI, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Fatigue is an important patient reported outcome in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) research. FACIT-Fatigue is a 13-item patient reported outcome (PRO)…
Abstract Number: 1505 • 2019 ACR/ARP Annual Meeting
Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Xenofon Baraliakos¹, Denis Poddubnyy ², Frank Behrens ³, Cinzia Curiale ⁴, Miriam Tarallo ⁴, Ana Cristina Hernandez Daly ⁵, Olaf Behmer ⁶, Joseph Cappelleri ⁷, Nicholas Hudson ⁸ and Christen Gray ⁸, ¹Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ³Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Pfizer Inc., Rome, Italy, ⁵Pfizer Inc., Athens, Greece, ⁶Pfizer Inc., Berlin, Germany, ⁷Pfizer Inc, Groton, CT, ⁸IQVIA, London, United Kingdom
Background/Purpose: Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treatment includes biologics, prescribed on a long-term basis. As persistence data from real-world practice are limited, the…
Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Daniela DiGuiseppe ², Anne Gitte Loft ³, Manuel Pombo-Suarez ⁴, Herman Mann ⁵, Ziga Rotar ⁶, Florenzo Iannone ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Kari K. Eklund ¹⁰, Bjorn Gudbjornsson ¹¹, Catalin Codreanu ¹², Sema Yılmaz ¹³, Johan Askling ¹⁴, Carlos Sánchez-Piedra ¹⁵, Karel Pavelka ⁵, Matija Tomsic ¹⁶, Fabrizio Conti ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Nina Trokovic ²⁰, Thorvardur J Love ²¹, Ruxandra IONESCU ²², Yavuz Pehlivan ²³, Michael J. Nissen ²⁴, Gary Macfarlane ²⁵, Irene van der Horst-Bruinsma ²⁶, Stylianos Georgiadis ²⁷, Lykke Midtbøll Ørnbjerg ²⁸, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ¹⁴Karolinska Institutet, Stockholm, Sweden, ¹⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁷Sapienza University of Rome, Rome, Italy, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰Helsinki University Central Hospital, Helsinki, Finland, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²SPITALUL CLINIC SFANTA MARIA, Bucharest, ²³Uludağ University, Bursa, Turkey, ²⁴University Hospital Geneva, Geneva, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…
Abstract Number: 2446 • 2019 ACR/ARP Annual Meeting
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Elsa Vieira-Sousa¹, Mónica Eusébio ², Pedro Ávila-Ribeiro ³, Nikita Khmelinskii ⁴, Rita Cruz-Machado ⁵, Teresa Martins Rocha ⁶, Miguel Bernardes ⁷, Daniela Santos-Faria ⁸, Joana Leite Silva ⁸, Helena Santos ⁹, Cláudia Miguel ¹⁰, Pedro Carvalho ¹¹, Tiago Costa ¹², Lídia Teixeira ¹³, Tiago Meirinhos ¹⁴, Patrícia Nero ¹⁵, João Eurico Fonseca ³ and Maria José Santos ¹⁶, ¹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²Portuguese Society of Rheumatology, Lisbon, Portugal, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ⁴Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁵Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHULN; Lisboa, Portugal. Centro Académico de Medicina de Lisboa, Portugal., Lisbon, Portugal, ⁶Rheumatology Department, Porto, Porto, Portugal, ⁷Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, ⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Rheumatology Department, CHUC and CHUA, Faro, Portugal, ¹²Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ¹³Rheumatology Department, HGO, Almada, Portugal, ¹⁴Rheumatology Department, CHBV, Aveiro, Portugal, ¹⁵Hospital CUF Descobertas, Lisbon, Portugal, ¹⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal
Background/Purpose: The impact of gender on tumor necrosis factor inhibitors (TNFi) effectiveness has been poorly studied in Psoriatic Arthritis (PsA) patients. The objective of this…
Abstract Number: 2466 • 2019 ACR/ARP Annual Meeting
Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients
Dalifer Freites Nuñez¹, Leticia León ², Pia Lois ³, Alfredo Madrid García ⁴, Judit Font Urgelles ⁵, Cristina Vadillo Font ⁶, lydia Abasolo Alcazar ⁶, Juan Angel Jover Jover ⁶, Benjamín Fernández Gutiérrez ⁷ and Luis Rodríguez-Rodríguez ⁴, ¹Hospital Clínico San Carlos, MADRID, Spain, ²Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ³Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁴Fundación para la Investigación Biomedica, Madrid, Spain, ⁵HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain, ⁶HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Psoriatic arthritis (PsA) is consider a multifaceted disease, with patients reporting lower health-related quality of life (HRQoL). Data of burden of disease is substantial…
Abstract Number: 2486 • 2019 ACR/ARP Annual Meeting
Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis
Halise Hande Gezer¹, Mehmet Tuncay Duruoz ², Kemal Nas ³, Erkan Kilic ⁴, Betul Sargin ⁵, Sevtap Acer Kasman ², Hakan Alkan ⁶, Nilay Sahin ⁷, Gizem Cengiz ⁸, Nihan Cuzdan ⁹, Ilknur Albayrak Gezer ¹⁰, Dilek Keskin ¹¹, Cevriye Mulkoglu ¹², Hatice Resorlu ¹³, Ismihan Sunar ¹⁴, Ajda Bal ¹⁵, Okan Kucukakkas ¹⁶, Ozan Volkan Yurdakul ¹⁶, Meltem Alkan Melikoglu ¹⁷, Yildiray Aydin ³, Fikriye Figen Ayhan ¹⁸, Hatice Bodur ¹⁹, Mustafa Calis ⁸, Erhan Capkin ²⁰, Gul Devrimsel ²¹, Kevser Gök ²², Sami Hizmetli ²³, Ayhan Kamanli ³, Yasar Keskin ¹⁶, Hilal Kocabas ²⁴, Oznur Kutluk ²⁵, Nesrin Sen ²⁶, Omer Faruk Sendur ²⁷, Ibrahim Tekeoglu ³, Sena Tolu ²⁸, Murat Toprak ²⁹ and Tiraje Tuncer ²⁵, ¹Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ³Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, ⁴Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, ⁵Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, ⁶Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, ⁷Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, ⁸Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, ⁹Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, ¹⁰Selçuk University School of Medicine, PMR Department, Konya, Turkey, ¹¹Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, ¹²Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹³Çanakkale Onsekiz Mart University School of Medicine, PMR Department, Çanakkale, Turkey, ¹⁴Ankara Unversity School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Turkey, ¹⁵Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹⁶Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, ¹⁷Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, ¹⁸Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, ¹⁹Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, ²⁰Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, ²¹Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, ²²Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, ²³Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, ²⁴Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, ²⁵Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, ²⁶Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, ²⁷Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, ²⁸Medipol University School of Medicine, PMR Department, İstanbul, Turkey, ²⁹Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey
Background/Purpose: Disease activity of psoriatic arthritis (PsA) is affected by many parameters including joint, spinal and skin involvement, enthesitis, dactylitis and pain. According to disease…
Abstract Number: 2509 • 2019 ACR/ARP Annual Meeting
Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study
Panagiotis Athanassiou ¹, Athina Theodoridou ², Eftychia Maria Koukli ³, Athanasios Georgountzos ⁴, Panagiotis Vlachoyiannopoulos ⁵, Ioannis Kallitsakis ⁶, Lazaros Sakkas ⁷, Aikaterini Matsouka Dapola ⁸, Souzana Gazi ⁹, Panagiotis Georgiou ¹⁰, Patricia Gorecki ¹¹ and Christos Gkamaloutsos¹², ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Thessaloniki, Greece, ³Private Practice, Kifisia-Athens, Greece, ⁴General Hospital of Athens “G. Gennimatas”, Athens, Greece, ⁵University General Hospital of Athens “Laiko”, Athens, Greece, ⁶Private Practice, Chania, Greece, ⁷University General Hospital of Larissa, Larissa, Greece, ⁸Private Practice, Cholargos-Athens, Greece, ⁹General Hospital of Athens “KAT”, Athens, Greece, ¹⁰General Hospital of Patras “Agios Andreas”, Patras, Greece, ¹¹Janseen-Cilag UK, High Wycombe, United Kingdom, ¹²Janssen-Cilag Pharmaceutical SACI(Greece), Athens, Greece
Background/Purpose: Psoriatic arthritis (PsA) is a chronic progressive inflammatory arthropathy associated with psoriasis (PsO). PsA places a considerable burden, adversely affecting health-related quality of life…
Abstract Number: 2879 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang ¹, Yu-fei Hao ², Sheng-xiao Zhang², Quan-run Li ³, Jing-yuan Yang ³, Jia-qian Zhang ¹, Guang-ying Liu ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a…
Abstract Number: 290 • 2019 ACR/ARP Annual Meeting
In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease and its assessment is sometimes difficult. Perception of disease activity by patient and physician is frequently discordant…
Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Fatima Abji¹, Anastasiya Muntyanu ², Remy Pollock ¹, Rohan Machhar ¹, Justine (Yang) Ye ³, Vinod Chandran ⁴ and Dafna Gladman ⁵, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University of Toronto, University Health Network, Toronto, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…
Abstract Number: 1204 • 2019 ACR/ARP Annual Meeting
Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial
M. Elaine Husni¹, Diane Harrison ², Elizabeth Hsia ³, Eric K H Chan ², Chenglong Han ², Shelly Kafka ⁴, Kim Hung Lo ², Lilianne Kim ² and Arthur Kavanaugh ⁵, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: In the randomized, phase 3, GO-VIBRANT study, more patients with psoriatic arthritis (PsA) achieved ACR 20/50/70 after 24 weeks IV treatment with the anti-TNFa…
Abstract Number: 1516 • 2019 ACR/ARP Annual Meeting
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Martin Bergman¹, Yusuf Yazici ², Laura Coates ³, Josef Smolen ⁴, M. Elaine Husni ⁵, Sven Richter ⁶, Lichen Teng ⁶ and Arthur Kavanaugh ⁷, ¹Drexel University College of Medicine, Stockholm, Sweden, ²New York University School of Medicine, New York, ³University of Oxford, Oxford, United Kingdom, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁶Celgene Corporation, Summit, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) is an outcome measure of disease activity entirely derived from patient self-reported measures (Health Assessment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].